CSF proteomics of semorinemab Alzheimer's disease trials identifies cell-type specific signatures. - Abdel-Haleem AM; Casavant E; Toth B; Teng E; Monteiro C; Pandya NJ; Glock C; Hoogenraad CC; Friedman BA; Yeh FL; Anania VG; Novikova G (Brain : a journal of neurology, 2026)